Rochester, NY -- (ReleaseWire) -- 07/20/2018 --Investor News Source Featured Stock Profile: Innovest Global Inc. (OTCPink:IVST) (the "Company" or "Innovest"), a diversified holding company with operations in commercial and industrial products and services, launched its anticipated Biotechnology & Health Services Division today with the acquisition of a twenty percent interest in StemVax Therapeutics, a Translational Biotechnology Company that is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors.
StemVax Glioblast (SVX-GB) is a cancer vaccine, which is a medication that stimulates or restores the immune system's ability to fight an existing cancer by strengthening the body's natural defenses against the cancer cells. It is a meaningful technology, which could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors.
Different than Innovest's wholly owned operating companies, the StemVax business model is one that enables Innovest to have a stake in potentially valuable intellectual property, which StemVax will attempt to proliferate by licensing to well established health research organizations experienced with taking such products to market.
Dr. Dwain Morris-Irvin, President of Innovest's new Biotechnology & Health Services Division, founded StemVax in 2014, and is its Chief Science Officer. "I am extremely excited to be launching this Division. We have spent a lot of time working to ensure it has the elements we feel will best position it for success, and starting with StemVax is very exciting," said Dr. Morris-Irvin. Dan Martin, CEO of Innovest Global echoed those comments and added, "Scientists and health professionals face difficult and unique challenges when considering how to advance their efforts in a commercial environment. Our Biotechnology & Health Services Division, under Dwain's leadership, is the perfect bridge. StemVax has remarkable technology that has the potential to achieve breakthrough results for patients and is the perfect starting point."
More about Dr. Morris-Irvin:
Dr. Morris-Irvin's PhD is in Pharmacology and Developmental Neuroscience with an emphasis on neural stem cell fate and differentiation. His research focused on neural development and Notch Signaling in mammalian neural stem cells. He also worked as an NIH/NINDS Post-Doctoral Fellow in Dr. Anders Bjorklund laboratory in Lund, Sweden. There, his focus was on research projects that investigated the potential role of cell replacement therapy for patients with Parkinson's disease. They developed several protocols for the efficient generation of dopaminergic neurons from forebrain and ventral midbrain stem and progenitor cells.
Additionally, Dr. Morris-Irvin led research investigations in the role of adaptive immunity in Parkinson's disease. He also developed two patents in the area of immunotherapy for brain tumor patients, specifically Glioblastoma Multiforme (GBM). His research team focused on molecular mechanisms that impart therapeutic resistance in cancer cells, including cancer stem cells. They utilized this data to develop novel immunotherapies for brain tumor patients.
About Innovest Global, Inc.
Innovest Global, Inc. (OTC Markets:IVST) is in the Conglomerates industry, a diversified holding company with operations in commercial and industrial products and services, energy, biotechnology, and health services. Innovest Global utilizes novel technology and marketing to efficiently acquire customers. Our primary growth strategy is to acquire existing companies in a select few industries, and attract new customers in cost effective ways. Currently, we have a Commercial & Industrial Division, and a Biotechnology & Health Services Division.
For more information, please visit: http://www.innovestglobal.com, and follow us on Twitter @innovestglobal.
Disclaimer:
This report/release/advertisement is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: Investor News Source and its employees are not a Registered Investment Advisors, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Everything you see is a paid advertisement and should not be considered financial advice or a solicitation to buy or sell stock. Always contact the financial institution and do your own research before buying any security which is at your own risk. Investor News Source is a digital marketing company located in Rochester New York.
